Claims

1. A vaccine/inhibitor combination comprising:

(i) as vaccine an RNA vaccine comprising at least one RNA, wherein the at least one RNA is an mRNA comprising at least one open reading frame (ORF) coding for at least one antigen and

(ii) as inhibitor a composition comprising a PD-1 pathway inhibitor,

wherein the PD-1 pathway inhibitor is an antagonistic antibody, which is directed against PD-1.

2. The combination according to claim 1, wherein the antibody directed against PD-1 is BMS-936558/MDX1106, CT-011 or MK-3475.

3. The combination according to claim 1 or 2, wherein the at least one RNA of the RNA vaccine is an isolated RNA.

4. The combination according to any one of claims 1-3, wherein the at least one RNA of the RNA vaccine is a stabilized RNA.

5. The combination according to any one of claims 1-4, wherein the at least one RNA of the RNA vaccine is at least partially G/C modified.

6. The combination according to any one of claims 1-5, wherein the at least one RNA of the RNA vaccine comprises a codon-optimized region.

7. The combination according to any one of claims 1-6, wherein the at least one RNA of the RNA vaccine is complexed with a carrier.

8. The combination according to claim 7, wherein the carrier is a cationic or polycationic compound or a polymeric carrier.

9. A pharmaceutical composition comprising:

(i) an RNA vaccine comprising at least one RNA comprising at least one open reading frame coding for at least one antigen as defined in any one of the preceding claims and

(ii) a PD-1 pathway inhibitor as defined in any one of the preceding claims.

10. A PD-1 pathway inhibitor as defined in any one of the preceding claims for use in therapy in combination with an RNA vaccine as defined in any one of the preceding claims.

11. An RNA vaccine as defined in any one of the preceding claims for use in therapy in combination with a PD-1 pathway inhibitor as defined in any one of the preceding claims.